Hedge Funds Capture Big Early Gains in Select Biotech IPOs — With One Notable Exception
Major funds, including Suvretta, RA Capital, and Viking, took sizable stakes ahead of these offerings, positioning themselves to benefit from the sector’s strongest debuts.